Immunologic Deficiency Syndromes
11 treatments and conditions followed through the public trial records. Not medical advice.How a status is set
Lists this condition and the narrower ones beneath it. A condition is not a diagnosis.
Treatments and conditions
Immunologic Deficiency Syndromes| Treatment and condition | Where it stands | Trials |
|---|
| Base-edited hematopoietic stem and progenitor cells + ALEMTUZUMAB + Busulfan + FILGRASTIM + PALIFERMIN + PLERIXAFOR for x-linked combined immunodeficiency diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Direct intravenous injection of ivlv-X1 lentiviral vector for x-linked combined immunodeficiency diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Haploidentical Hematopoietic Cell Transplantation for primary immunodeficiency diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paxlovid 10 days for immunologic deficiency syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Paxlovid 10 days + REMDESIVIR for immunologic deficiency syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Paxlovid 5 days for immunologic deficiency syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
|---|
| Paxlovid 5 days + REMDESIVIR for immunologic deficiency syndromes | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for immunologic deficiency syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 2 Established Dose from prior study, NCT03810196 for immunologic deficiency syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Phase 2 Maximum Tolerated Dose determined in Phase 1 for immunologic deficiency syndromes | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|
| Rivogenlecleucel + rimiducid for primary immunodeficiency diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
|---|